論文 - 詳細
| RRC ID | 69688 |
|---|---|
| 著者 | Kimura A, Kamimura K, Ohkoshi-Yamada M, Shinagawa-Kobayashi Y, Goto R, Owaki T, Oda C, Shibata O, Morita S, Sakai N, Abe H, Yokoo T, Sakamaki A, Kamimura H, Terai S. |
| タイトル | Effects of a novel selective PPARα modulator, statin, sodium-glucose cotransporter 2 inhibitor, and combinatorial therapy on the liver and vasculature of medaka nonalcoholic steatohepatitis model. |
| ジャーナル | Biochem Biophys Res Commun |
| Abstract |
OBJECTIVE:Nonalcoholic steatohepatitis (NASH) is a disease entity with an increasing incidence, with involvement of several metabolic pathways. Various organs, including the liver, kidneys, and the vasculature, are damaged in NASH, indicating the urgent need to develop a standard therapy. Therefore, this study was conducted to investigate the effects of drugs targeting various metabolic pathways and their combinations on a high-fat diet (HFD)-induced NASH medaka model. METHODS:To investigate the effects of drugs on vascular structures, the NASH animal model was developed using the fli::GFP transgenic medaka fed with HFD at 20 mg/fish daily. The physiological changes, histological changes in the liver, vascular structures in the fin, and serum biochemical markers were evaluated in a time-dependent manner after treatment with selective peroxisome proliferator-activated receptor α modulator (pemafibrate), statin (pitavastatin), sodium-glucose cotransporter 2 inhibitor (tofogliflozin), and their combinations. Furthermore, to determine the mechanisms underlying the effects, whole transcriptome sequencing was conducted using medaka liver samples. RESULTS:Histological analyses revealed significant suppression of fat accumulation and fibrotic changes in the liver after treatment with drugs and their combinations. The expression levels of steatosis- and fibrosis-related genes were modified by the treatments. Moreover, the HFD-induced vascular damages in the fin exhibited milder changes after treatment with the drugs. CONCLUSION:The effects of treating various metabolic pathways on the medaka body, liver, and vascular structures of the NASH medaka model were evidenced. Moreover, to our knowledge, this study is the first to report whole genome sequence and gene expression evaluation of medaka livers, which could be helpful in clarifying the molecular mechanisms of drugs. |
| 巻・号 | 596 |
| ページ | 76-82 |
| 公開日 | 2022-3-12 |
| DOI | 10.1016/j.bbrc.2022.01.086 |
| PII | S0006-291X(22)00112-7 |
| PMID | 35121372 |
| MeSH | Animal Fins / blood supply Animal Fins / drug effects* Animals Animals, Genetically Modified Benzhydryl Compounds / pharmacology Benzoxazoles / pharmacology Butyrates / pharmacology Diet, High-Fat / adverse effects Disease Models, Animal Exome Sequencing / methods Gene Ontology Glucosides / pharmacology Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacology* Liver / drug effects* Liver / metabolism Liver / pathology Non-alcoholic Fatty Liver Disease / etiology Non-alcoholic Fatty Liver Disease / genetics* Non-alcoholic Fatty Liver Disease / metabolism Oryzias / genetics* Oryzias / metabolism PPAR alpha / genetics* PPAR alpha / metabolism Quinolines / pharmacology Reverse Transcriptase Polymerase Chain Reaction Sodium-Glucose Transporter 2 Inhibitors / pharmacology* Transcriptome / drug effects Transcriptome / genetics |
| IF | 2.985 |
| リソース情報 | |
| メダカ | fli::GFP (TG1206) |